PhD (1991) in “Docteur ès Sciences Pharmaceutiques” (La plus grande distinction avec les
félicitations du júri), Université Catholique de Louvain, Brussels, Belgium
Faculdade de Farmácia, Universidade de Lisboa — Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
Rogério Gaspar has more than 20 years experience in the design and evaluation of nanoparticles and liposomes for drug (e.g. Leishmaniasis and cancer) and gene (cytosolic) delivery. More recently, these interests have broadened to other aspects of the nanomedicine field including the design of vectors for MRI imaging and also understanding the cellular mechanisms that govern the action of nanomedicines. He has a long career in regulatory affairs and regulatory science both in academic, regulatory and industrial positions, at national and international levels. He frequently participates and coordinates international activities dealing with regulatory aspects of nanomedicines (including European Science Foundation, European Commission, European Medicines Agency, European Federation of Pharmaceutical Sciences – EUFEPS, TI Pharma – NL).
M. Videira , A. Arranja , D. Rafael , R. Gaspar – Preclinical development of siRNA therapeutics: towards the match between fundamental science and engineered systems. Nanomedicine: Nanotechnology, Biology, and Medicine, published online 11 December 2013, DOI: 10.1016/j.nano.2013.11.018 2013-12
Joana M. Silva, Mafalda Videira, Rogério Gaspar, Véronique Préat, Helena F. Florindo. Immune System Targeting by Nanoparticles for Cancer Vaccines. J Control Release 2013; 168:179-199
Rogério Gaspar. Nanoparticles: Pushed off target with proteins. Nature Nanotechnology 2013; 8, 79–80 doi:10.1038/nnano.2013.11.
Klopp, A.H. and Lacerda, L. and Gupta, A. and Debeb, B.G. and Solley, T. and Li, L. and Spaeth, E. and Xu, W. and Zhang, X. and Lewis, M.T. and Reuben, J.M. and Krishnamurthy, S. and Ferrari, M. and Gaspar, R. and Buchholz, T.A. and Cristofanilli, M. and Marini, F. and Andreeff, M. and Woodward, W.A. Mesenchymal stem cells promote mammosphere formation and decrease E-Cadherin in normal and malignant breast cells. PLoS One 2010;5 (8): e12180- e12180.
Gaspar R, Duncan R. Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics. Adv Drug Deliv Rev. 2009; 61(13):1220-31.